|
KMID : 0939920140460010019
|
|
대한암학회지
2014 Volume.46 No. 1 p.19 ~ p.26
|
|
|
A Randomized Double-Blind, Double-Dummy, Multicenter Trial of Azasetron versus Ondansetron to Evaluate Efficacy and Safety in the Prevention of Delayed Nausea and Vomiting Induced by Chemotherapy
|
|
Lee Hee-Yeon
Kim Hoon-Kyo
Lee Kyung-Hee
Kim Bong-Seog
Song Hong-Suk
Yang Sung-Hyun
Kim Joon-Hee
Kim Yeul-Hong
Kim Jong-Gwang
Kim Sang-We
Kim Dong-Wan
Kim Si-Young
Park Hee-Sook
|
|
|
Abstract
|
|
|
Purpose: This study was conducted to evaluate the efficacy and safety of azasetron compared to ondansetron in the prevention of delayed chemotherapy-induced nausea and vomiting.
Materials and Methods: This study was a multi-center, prospective, randomized, double-dummy, double-blind and parallel-group trial involving 12 institutions in Korea between May 2005 and December 2005. A total of 265 patients with moderately and highly emetogenic chemotherapy were included and randomly assigned to either the azasetron or ondansetron group. All patients received azasetron (10 mg intravenously) and dexamethasone (20 mg intravenously) on day 1 and dexamethasone (4 mg orally every 12 hours) on days 2-4. The azasetron group received azasetron (10 mg orally) with placebo of ondansetron (orally every 12 hours), and the ondansetron group received ondansetron (8 mg orally every 12 hours) with placebo of azasetron (orally) on days 2-6.
Results: Over days 2-6, the effective ratio of complete response in the azasetron and ondansetron groups was 45% and 54.5%, respectively (95% confidence interval, -21.4 to 2.5%). Thus, the non-inferiority of azasetron compared with ondansetron in delayed chemotherapy-induced nausea and vomiting was not proven in the present study. All treatments were well tolerated and no unexpected drug-related adverse events were reported. The most common adverse events related to the treatment were constipation and hiccups, and there were no differences in the overall incidence of adverse events.
Conclusion: In the present study, azasetron showed inferiority in the control of delayed chemotherapy-induced nausea and vomiting compared with ondansetron whereas safety profiles were similar between the two groups.
|
|
|
KEYWORD
|
|
|
Vomiting, Vomiting/chemically induced, Vomiting/prevention and control, Antineoplastic agents, Serotonin antagonists, Azasetron, Ondansetron
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
    
|
|